> top > docs > PubMed:35351535 > annotations

PubMed:35351535 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-135 Sentence denotes Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes:
T2 136-166 Sentence denotes A randomized controlled trial.
T3 167-178 Sentence denotes BACKGROUND:
T4 179-305 Sentence denotes Inflammation is closely associated with atherosclerosis and plays a crucial role in the development of cardiovascular disease.
T5 306-409 Sentence denotes Metformin sensitizes body cells to insulin, which may cause a reduction of atherogenic lipid fractions.
T6 410-547 Sentence denotes Low neuregulin-4 (Nrg-4) levels, an adipokine, are linked to obesity, insulin resistance, impaired glucose tolerance and type 2 diabetes.
T7 548-559 Sentence denotes OBJECTIVES:
T8 560-833 Sentence denotes We assessed the effect of oral supplementation with metformin on glycemic control, neuregulin-4 levels and carotid intima media thickness (CIMT) as a marker for subclinical atherosclerosis in adolescents with type 1 diabetes mellitus (T1DM) and microvascular complications.
T9 834-842 Sentence denotes METHODS:
T10 843-1051 Sentence denotes This randomized placebo-controlled trial included 80 type 1 diabetic patients with microvascular complications who were randomly divided to receive either 24 weeks of metformin 500 mg/day or matching placebo.
T11 1052-1225 Sentence denotes Fasting blood glucose (FBG), HbA1c, C-reactive protein (CRP), urinary albumin creatinine ratio (UACR), lipid profile, Nrg-4 and CIMT were assessed at baseline and study end.
T12 1226-1234 Sentence denotes RESULTS:
T13 1235-1336 Sentence denotes Both groups were well-matched as regards baseline clinical and laboratory data (p greater than 0.05).
T14 1337-1591 Sentence denotes After 24-weeks, metformin therapy for the intervention group resulted in a significant decrease of HbA1c, CRP, UACR, total cholesterol and CIMT while Nrg-4 levels were increased compared with baseline levels (p < 0.001) and with placebo group(p < 0.001).
T15 1592-1688 Sentence denotes Baseline Nrg-4 levels were negatively correlated to FBG, HbA1c, total cholesterol, CRP and CIMT.
T16 1689-1718 Sentence denotes Metformin was well-tolerated.
T17 1719-1731 Sentence denotes CONCLUSIONS:
T18 1732-2028 Sentence denotes Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis.
T1 0-135 Sentence denotes Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes:
T2 136-166 Sentence denotes A randomized controlled trial.
T3 167-178 Sentence denotes BACKGROUND:
T4 179-305 Sentence denotes Inflammation is closely associated with atherosclerosis and plays a crucial role in the development of cardiovascular disease.
T5 306-409 Sentence denotes Metformin sensitizes body cells to insulin, which may cause a reduction of atherogenic lipid fractions.
T6 410-547 Sentence denotes Low neuregulin-4 (Nrg-4) levels, an adipokine, are linked to obesity, insulin resistance, impaired glucose tolerance and type 2 diabetes.
T7 548-559 Sentence denotes OBJECTIVES:
T8 560-833 Sentence denotes We assessed the effect of oral supplementation with metformin on glycemic control, neuregulin-4 levels and carotid intima media thickness (CIMT) as a marker for subclinical atherosclerosis in adolescents with type 1 diabetes mellitus (T1DM) and microvascular complications.
T9 834-842 Sentence denotes METHODS:
T10 843-1051 Sentence denotes This randomized placebo-controlled trial included 80 type 1 diabetic patients with microvascular complications who were randomly divided to receive either 24 weeks of metformin 500 mg/day or matching placebo.
T11 1052-1225 Sentence denotes Fasting blood glucose (FBG), HbA1c, C-reactive protein (CRP), urinary albumin creatinine ratio (UACR), lipid profile, Nrg-4 and CIMT were assessed at baseline and study end.
T12 1226-1234 Sentence denotes RESULTS:
T13 1235-1336 Sentence denotes Both groups were well-matched as regards baseline clinical and laboratory data (p greater than 0.05).
T14 1337-1591 Sentence denotes After 24-weeks, metformin therapy for the intervention group resulted in a significant decrease of HbA1c, CRP, UACR, total cholesterol and CIMT while Nrg-4 levels were increased compared with baseline levels (p < 0.001) and with placebo group(p < 0.001).
T15 1592-1688 Sentence denotes Baseline Nrg-4 levels were negatively correlated to FBG, HbA1c, total cholesterol, CRP and CIMT.
T16 1689-1718 Sentence denotes Metformin was well-tolerated.
T17 1719-1731 Sentence denotes CONCLUSIONS:
T18 1732-2028 Sentence denotes Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis.

maxiaofeng52_800_3

Id Subject Object Predicate Lexical cue
T1 119-134 DP denotes type 1 diabetes
T2 769-793 DP denotes type 1 diabetes mellitus
T3 795-799 DP denotes T1DM
T4 1844-1848 DP denotes T1DM
T5 10-19 CI denotes metformin
T6 612-621 CI denotes metformin
T7 1010-1019 CI denotes metformin
T8 1353-1362 CI denotes metformin
T9 1737-1746 CI denotes metformin
T10 896-911 DP denotes type 1 diabetic
T11 306-315 CI denotes Metformin
T12 1689-1698 CI denotes Metformin
T13 1043-1050 CI denotes placebo
T14 859-866 CI denotes placebo
T15 1566-1573 CI denotes placebo

wangzhuo19_800_3

Id Subject Object Predicate Lexical cue
T1 10-19 CI denotes metformin
T10 1689-1698 CI denotes Metformin
T11 119-134 DP denotes type 1 diabetes
T12 769-793 DP denotes type 1 diabetes mellitus
T13 795-799 DP denotes T1DM
T14 1844-1848 DP denotes T1DM
T15 896-911 DP denotes type 1 diabetic
T2 612-621 CI denotes metformin
T3 1010-1019 CI denotes metformin
T4 1353-1362 CI denotes metformin
T5 1737-1746 CI denotes metformin
T6 859-866 CI denotes placebo
T7 1043-1050 CI denotes placebo
T8 1566-1573 CI denotes placebo
T9 306-315 CI denotes Metformin